|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CtBP2 proteins are ubiquitously expressed in all lines and tumour samples.
|
20964627 |
2010 |
|
Epithelial ovarian cancer
|
0.020 |
Biomarker
|
disease |
BEFREE |
C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.
|
22945647 |
2013 |
|
Carcinoma, Ovarian Epithelial
|
0.020 |
Biomarker
|
disease |
BEFREE |
C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.
|
22945647 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
C-terminal binding protein-2 (CtBP2), as a transcriptional co-repressor, has been shown to mediate the repression of p16(INK4A) , a tumor suppressor gene product, in primary human cells.
|
23255392 |
2013 |
|
Epithelial ovarian cancer
|
0.020 |
Biomarker
|
disease |
BEFREE |
CtBP2 is an ovarian cancer oncogene that may play a significant role in epigenetically silencing BRCA1 function in sporadic epithelial ovarian cancer.
|
23730208 |
2013 |
|
Ovarian Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CtBP2-specific inhibitors, such as MTOB, may be effective adjunct therapies in the management of patients with CtBP2-positive ovarian carcinoma.
|
23730208 |
2013 |
|
Tumor Initiation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
C-terminal binding protein-2 (CtBP2) is a CtBP-family member which plays a significant role in tumor initiation, progression and response to therapy.
|
24835310 |
2014 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
C-terminal binding protein 2 (CtBP2) is a transcriptional co-repressor that promotes cancer cell migration and invasion by inhibiting multiple tumor suppressor genes that contribute to cell mobility and adhesion.
|
25686837 |
2015 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
C-terminal binding protein 2 (CtBP2) is a transcriptional co-repressor that promotes cancer cell migration and invasion by inhibiting multiple tumor suppressor genes that contribute to cell mobility and adhesion.
|
25686837 |
2015 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
C-terminal binding protein 2 (CtBP2) is a transcriptional co-repressor that promotes cancer cell migration and invasion by inhibiting multiple tumor suppressor genes that contribute to cell mobility and adhesion.
|
25686837 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
C-terminal binding protein 2 (CtBP2) is a transcriptional co-repressor that promotes cancer cell migration and invasion by inhibiting multiple tumor suppressor genes that contribute to cell mobility and adhesion.
|
25686837 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CtBP2, as a transcriptional corepressor of epithelial-specific genes, has been reported to promote tumor due to upregulating epithelial-mesenchymal transition (EMT) in cancer cells.
|
25820824 |
2015 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
CtBP2 induced epithelial-to-mesenchymal transition (EMT) and repressed PTEN to increase proliferation rate, migration, and invasion in GC cells.
|
28404932 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
C-terminal binding protein-2 (CtBP2) enhances cancer proliferation and metastasis.
|
28412731 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
C-terminal binding protein-2 (CtBP2) enhances cancer proliferation and metastasis.
|
28412731 |
2017 |
|
polyps
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Ctbp2 heterozygosity increased the median survival of Apc<sup>min/+</sup> mice from 21 to 48 weeks, and reduced polyp formation by 90%, with Ctbp2<sup>+/-</sup> polyps exhibiting reduced levels of β-catenin and its oncogenic transcriptional target, cyclin D1.
|
28414304 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CtBP2 is thus a druggable transforming oncoprotein critical for the evolution of neoplasia driven by Apc mutation.
|
28414304 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
CTBP2 restoration overturned cell viability and invasion suppression mediated by NEAT1 knockdown or miR-129 overexpression.
|
29147064 |
2017 |
|
Esophageal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
C-terminal binding protein‑2 mediates cisplatin chemoresistance in esophageal cancer cells via the inhibition of apoptosis.
|
29658564 |
2018 |
|
Esophageal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
C-terminal binding protein‑2 mediates cisplatin chemoresistance in esophageal cancer cells via the inhibition of apoptosis.
|
29658564 |
2018 |
|
Malignant neoplasm of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
C-terminal binding protein‑2 mediates cisplatin chemoresistance in esophageal cancer cells via the inhibition of apoptosis.
|
29658564 |
2018 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CtBP2 expression was higher in HBV-related HCC tissues than in paracancerous tissues.
|
30151388 |
2018 |
|
Intestinal Polyposis
|
0.010 |
Biomarker
|
disease |
BEFREE |
C-terminal binding protein 2 (CtBP2) drives intestinal polyposis in the <i>Apc</i><sup>
|
30197752 |
2018 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
CtBP2 was demonstrated to modulate cell migration and invasion via JAK1/Stat3 signaling pathway in fetal osteoblast cells.
|
31214864 |
2019 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
|
20512145 |
2010 |